In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures.
Related People
The Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology) and the Chief of the Division of Gastroenterology for the Mount Sinai Health System
